Drug Trial Radar · NCT04837040
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
58
Actual
Start
May 12, 2021
Primary completion
Jul 10, 2023
Study completion May 29, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.
Conditions
- Acromegaly
Interventions
PaltusotineDrug
Paltusotine, tablets, once daily by mouth
PlaceboDrug
Placebo, tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Maintain Biochemical Response in IGF-1 (≤1.0× the Upper Limit of Normal [ULN]) at the End of the Randomized Control Phase (EOR)Time frame: 36 Weeks
Locations
39 sites in 14 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Los Angeles, California
Crinetics Study Site
Torrance, California
Crinetics Study Site
Baltimore, Maryland
Crinetics Study Site
Boston, Massachusetts
Crinetics Study Site
Philadelphia, Pennsylvania
Crinetics Study Site
Pittsburgh, Pennsylvania
Crinetics Study Site
Nashville, Tennessee
Crinetics Study Site
Córdoba, Argentina
Crinetics Study Site
CABA, Buenos Aires, Argentina
Crinetics Study Site
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Crinetics Study Site
Ghent, Belgium
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Fortaleza, Ceará, Brazil
Crinetics Study Site
Curitiba, Paraná, Brazil
Crinetics Study Site
Porto Alegre, Rio Grande do Sul, Brazil
Crinetics Study Site
Sofia, Bulgaria
Crinetics Study Site
Bron, France
Crinetics Study Site
Pessac, France
Crinetics Study Site
Budapest, Hungary
Crinetics Study Site
Pécs, Hungary
Crinetics Study Site
Beersheba, Israel
Crinetics Study Site
Petah Tikva, Israel
Crinetics Study Site
Roma, Italy
Crinetics Study Site
San Isidro, Lima region, Peru
Crinetics Study Site
Bydgoszcz, Poland
Crinetics Study Site
Poznan, Poland
Crinetics Study Site
Moscow, Russia
Crinetics Study Site
Moscow, Russia
Crinetics Study Site
Moscow, Russia
Crinetics Study Site
Kemerovo, Kemerovo Oblast, Russia
Crinetics Study Site
Novosibirsk, Novosibirsk Oblast, Russia
Crinetics Study Site
Novosibirsk, Novosibirsk Oblast, Russia
Crinetics Study Site
Samara, Samara Oblast, Russia
Crinetics Study Site
Kazan', Tatarstan Republic, Russia
Crinetics Study Site
Belgrade, Serbia
Crinetics Study Site
London, United Kingdom
Crinetics Study Site
Sheffield, South Yorkshire, United Kingdom
Crinetics Study Site
Coventry, West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.